Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (mast cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: urelumab, utomilumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 341 | 0.73 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5459
Sealed predictions
- TNFRSF9 in dopamine neurons, braak-0.14 (p 0.716) → -0.03 (p 0.944)receipt 5466
Swarm cases
receipt 5466: TNFRSF9 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.935, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.942, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.820, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.08, sign flips 8; without severely affected donors -0.02 (p 0.935, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TNFRSF9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts